China National Medicines Corp., Ltd. releases H1 2026 financial report

Summary

Sinopharm (国药股份) reported H1 2026 revenue of 26.73 billion RMB (+4.27% YoY) but a net profit decline of 7.25% to 880 million RMB etnet. While revenue stayed positive, Q2 performance was notably weaker with profits dropping 17.2% YoY, alongside a significant negative operating cash flow of -2.634 billion RMB . The company is currently navigating a transition toward value-added services amid intense centralized procurement pressure .

Impact Analysis

Sinopharm’s H1 results show a classic margin squeeze, but the real story is the accelerating decay in Q2. While H1 revenue grew 4.27% to 26.73 billion RMB, net profit fell 7.25% . The red flag is the Q2 profit plunge of 17.2% YoY, suggesting that centralized procurement and DRG reforms are hitting harder and faster than anticipated .

Market participants might be missing the liquidity signal: operating cash flow hit a staggering -2.634 billion RMB . For a distributor, negative cash flow in a tightening regulatory environment is a major tell of working capital stress. Management is clearly trying to pivot toward SPD and DTP services to find higher ground, but these haven’t yet scaled enough to offset the erosion of traditional distribution margins . I’d read this as a defensive signal. Until we see a floor on margins or a stabilization in cash flow, this looks like a value trap. The transition from growth to ‘stock competition’ is proving painful, and the bottom isn’t in yet.